Form 8-K - Current report:
SEC Accession No. 0001193125-25-132783
Filing Date
2025-06-02
Accepted
2025-06-02 07:36:42
Documents
13
Period of Report
2025-06-02
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d945167d8k.htm   iXBRL 8-K 25949
2 EX-99.1 d945167dex991.htm EX-99.1 22651
  Complete submission text file 0001193125-25-132783.txt   173524

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA inab-20250602.xsd EX-101.SCH 2834
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE inab-20250602_lab.xml EX-101.LAB 18736
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE inab-20250602_pre.xml EX-101.PRE 11696
15 EXTRACTED XBRL INSTANCE DOCUMENT d945167d8k_htm.xml XML 3752
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39692 | Film No.: 251013152
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)